GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Race Oncology Ltd (ASX:RAC) » Definitions » Forward Dividend Yield %

Race Oncology (ASX:RAC) Forward Dividend Yield % : 0.00% (As of Apr. 30, 2025)


View and export this data going back to 2016. Start your Free Trial

What is Race Oncology Forward Dividend Yield %?

As of today (2025-04-30), the Forward Annual Dividend Yield of Race Oncology is 0.00%.

As of today (2025-04-30), the Trailing Annual Dividend Yield of Race Oncology is 0.00%.

ASX:RAC's Forward Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.61
* Ranked among companies with meaningful Forward Dividend Yield % only.

Race Oncology's Dividends per Share for the six months ended in Dec. 2024 was A$0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison of Race Oncology's Forward Dividend Yield %

For the Biotechnology subindustry, Race Oncology's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Race Oncology's Forward Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Race Oncology's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Race Oncology's Forward Dividend Yield % falls into.


;
;

Race Oncology Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

Race Oncology  (ASX:RAC) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.

Race Oncology Forward Dividend Yield % Related Terms

Thank you for viewing the detailed overview of Race Oncology's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Race Oncology Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Race Oncology Ltd (ASX:RAC) » Definitions » Forward Dividend Yield %
Comparable Companies
ASX:IMU ASX:ALA ASX:PAR ASX:DXB ASX:ACW ASX:AGN ASX:RCE ASX:EZZ ASX:ATH ASX:LTP VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
N/A
Address
1 Macquarie Place, Level 36, Gateway, Sydney, NSW, AUS, 2000
Website
https://www.raceoncology.com
Race Oncology Ltd is a clinical stage biopharmaceutical company with a mission to be at the heart of cancer care. Its asset, bisantrene, is a small molecule chemotherapeutic. Bisantrene has a clinical history with demonstrated therapeutic benefits in both adult and pediatric patients, a well-characterized safety profile, and compelling clinical data demonstrating an anticancer effect and less cardiotoxicity over certain anthracyclines, such as doxorubicin. It has reformulated bisantrene (RC220) to address the high unmet needs of patients across multiple oncology indications, with a clinical focus on anthracycline combinations, where Race can deliver cardioprotection and enhanced anticancer activity in solid tumors.